

# **Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation**

Matt Stevenson,<sup>1\*</sup> Rachel Archer,<sup>1</sup> Jon Tosh,<sup>1</sup>  
Emma Simpson,<sup>1</sup> Emma Everson-Hock,<sup>1</sup> John Stevens,<sup>1</sup>  
Monica Hernandez-Alava,<sup>1</sup> Suzy Paisley,<sup>1</sup>  
Kath Dickinson,<sup>1</sup> David Scott,<sup>2</sup> Adam Young<sup>3</sup>  
and Allan Wailoo<sup>1</sup>

<sup>1</sup>School of Health and Related Research (SchARR), University of Sheffield, Sheffield, UK

<sup>2</sup>Department of Rheumatology, King's College Hospital NHS Foundation Trust, London, UK

<sup>3</sup>Department of Rheumatology, West Hertfordshire Hospitals NHS Trust, Hertfordshire, UK

\*Corresponding author

Corrigendum issued November 2016

Corrigendum DOI: 10.3310/hta20350-c201611

Original DOI: 10.3310/hta20350

This report should be referenced as follows:

Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, *et al.* Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. *Health Technol Assess* 2016;**20**(35).  
Corrigendum in *Health Technol Assess* 2016;**20**(35):611–614.

*Health Technology Assessment* is indexed and abstracted in *Index Medicus/MEDLINE*, *Excerpta Medica/EMBASE*, *Science Citation Index Expanded (SciSearch®)* and *Current Contents®/Clinical Medicine*.

## Corrigendum notice

### Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation

Matt Stevenson, Rachel Archer, Jon Tosh, Emma Simpson, Emma Everson-Hock, John Stevens, Monica Hernandez-Alava, Suzy Paisley, Kath Dickinson, David Scott, Adam Young and Allan Wailoo

This paper<sup>1</sup> is corrected as follows:

Table 209: Information in this table has been updated.

**TABLE 209** Deterministic base-case results using EULAR data directly: ERAS cDMARD HAQ progression and a moderate, MTX-experienced, RA population

First intervention in the strategy	Discounted costs	Discounted QALYs	CPQ compared with MTX strategy (£)	Incremental CPQ (£)
MTX	CiC information has been removed	CiC information has been removed	–	–
TCZ + MTX	CiC information has been removed	CiC information has been removed	51,559	Extendedly dominated
ABT i.v. + MTX	CiC information has been removed	CiC information has been removed	47,533	47,533
IFX + MTX	CiC information has been removed	CiC information has been removed	48,424	Dominated
ADA + MTX	CiC information has been removed	CiC information has been removed	51,472	Dominated
CTZ + MTX	CiC information has been removed	CiC information has been removed	50,467	Extendedly dominated
GOL + MTX	CiC information has been removed	CiC information has been removed	51,111	Extendedly dominated
ETN + MTX	CiC information has been removed	CiC information has been removed	51,436	95,714

CPQ, cost per QALY gained.

## Reference

1. Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, *et al.* Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. *Health Technol Assess* 2016;**20**(35).